RDIF: Sputnik V more effective against Omicron than Pfizer - Breaking The News
Download our appPlay StoreApp Store

RDIF: Sputnik V more effective against Omicron than Pfizer

EPA-EFE/CHAMILA KARUNARATHNE

The Russian Direct Investment Fund (RDIF) said on Thursday that the Sputnik V coronavirus vaccine offers much higher protection against the Omicron variant than the Pfizer/BioNTech jab.

Citing comparative research at the Italian National Institute of Infectious Diseases Lazzaro Spallanzani, the RDIF noted that the number of antibodies two doses of Sputnik V create against Omicron is more than double compared to the antibodies the double dose of the Pfizer vaccine creates.

Earlier, studies showed that both vaccines offered low protection against Omicron, while Pfizer itself announced it is working on a new version of the jab that would target Omicron and expects to have it ready by March.

Related Stocks
Pfizer
Related News
Vaccine stocks fall after RFK Jr.'s HHS nomination advances
Shares of vaccine makers, including Moderna, Pfizer, and BioNTech, dipped Tuesday after the Senate Finance Committee advanced Robert F. Kennedy Jr.'s nomination for Health and Human Services secretary.The 14-13 party-line vote moved the controversial pick to the Senate floor. Kennedy, known for his skepticism of vaccines, has drawn sharp criticism for his previous comments on vaccine safety.At 10:41 am ET, Moderna's stock fell 5.11% to $34.68,...
Pfizer sees $17.8 billion in Q4 revenue, tops estimates
Pfizer Inc. announced on Tuesday that its closing quarter revenue for fiscal 2024 landed at $17.8 billion, marking a 22% year-over-year increase and surpassing analysts' expectations.In the reported quarter, Pfizer saw $410 million in net income, rebounding from a $3.4 billion net loss in the same period last year. Diluted earnings per share climbed to $0.63, up from $0.10 in 2023. For the full year, revenue rose 7% to $63.6 billion, while net income surged...
Earnings preview: Alphabet, Disney, Amazon and more
This week's earnings cycle brings together some of the biggest players across tech, automotive, finance, and pharmaceutical sectors facing groundbreaking challenges set out by United States President Donald Trump's economic shift, as well as China upping the AI race stakes. Tech is continuing to dominate the conversation after shocking AI market movers emerged from the East, as Google's parent Alphabet anticipates $96.6 billion in revenue in the last quarter,...
Pfizer projects 2025 revenue to reach up to $64B
Pfizer Inc. released its fiscal 2025 guidance on Tuesday, forecasting annual revenue for next year to range between $61 billion and $64 billion, including steady sales of its COVID-19 products compared to 2024 levels.The pharmaceutical giant stated that it expects its adjusted diluted earnings per share (EPS) to range between $2.80 and $3.00, "reflecting anticipated operational growth of 10% to 18% year-over-year from the midpoint of our 2024 baseline...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.